

**JUSTIFICATION FOR BRAND NAME AWARDS IAW FAR 13.106-1(b)(ii)**  
(OVER MICRO-PURCHASE THRESHOLD(\$3K) BUT NOT EXCEEDING THE SAT (\$150K))

IAW [FAR13.104](#), COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW [FAR13.106-1\(b\)](#), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW [FAR13.106-3\(b\)\(3\)](#), COs are required to include additional statements ***explaining the absence of competition*** (see [13.106-1](#) for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW [FAR13.106-3\(b\)\(3\)](#). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

**1. PURCHASE REQUEST OR REQUISITION NUMBER:**

766-17-3-400-0526

**1A. PROJECT/TASK  
NUMBER**

**1B. ESTIMATED AMOUNT:**

Total Procurement: \$0

**2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE:**

**BRAND NAME:** Reclipsen—manufactured by Watson Laboratories Inc.

**3. Reclipsen**

**NDC -** 52544-0954-28

**Quantity:** 285

**Use:** Oral Contraceptive

**Manufacturer:** Watson Laboratories Inc.

**3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:**

Within the VHA brand name items may be prescribed by physicians when in their clinical judgment the brand name item will provide a better therapeutic outcome for patients. The brand name of the product is in the CMOP print name. Pharmacists legally have to fill the prescription as it was written.

Products have been prescribed for patients by VA Physicians. Pharmacy employees do not have the training and/or authority to countermand physician orders. *"Brand Specific"* products are the same thing as *"dispense as written"* on a physician prescription. No NDC substitutions are permitted. In the VA, Pharmacy Benefits Management (PBM) has determined that CMOP IDs in the National Drug File (NDF) will most always identify *"brand specific"* products in the VA PRINT NAME. This is not always inclusive where a particular NDC has been determined to be *"formulation specific"* by clinical evaluation performed by the PBM or in the case where only one product was recommended.

Lines Item 3, Reclipsen (NDC: 52544-0954-28), is specific to the description which was prescribed by the physician - This product is indicated for the prevention of pregnancy.

**4. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:**

NAC, FSS, and GSA Advantage were searched: no contract items were found.

**5. Contracting Officer's Certification:** *Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief.*

**Signature:** \_\_\_\_\_

**Date:** 05-19-2017

**Name:** \_\_\_\_\_

**Title:** \_\_\_\_\_

**Facility:** \_\_\_\_\_